Adenoid Cystic Carcinoma clinical trials at UCSF
3 research studies open to eligible people
Adenoid cystic carcinoma is a rare gland cancer that often affects the salivary glands. UCSF is running a study of an antibody‑drug conjugate for solid tumors. UCSF is also studying precise stereotactic radiotherapy given early when only a few metastases are present. UCSF is testing a MYB mRNA degrader to measure safety and anti‑tumor effects.
XMT-1660 in Participants With Solid Tumors
open to eligible people ages 18 years and up
A Study of XMT-1660 in Solid Tumors
San Francisco, California and other locations
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
open to eligible people ages 18 years and up
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: - Stereotactic Body Radiation Therapy (SBRT)
San Francisco, California and other locations
REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
open to eligible people ages 18 years and up
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
San Francisco, California and other locations
Our lead scientists for Adenoid Cystic Carcinoma research studies include Sue Yom Laura Huppert Hyunseok Kang.
Last updated: